Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid, Sherlock Biosciences Partner on SARS-CoV-2 Diagnostic Test

NEW YORK – Cepheid and Sherlock Biosciences said on Friday that they have formed a research collaboration to develop new molecular diagnostic tests, using Sherlock Biosciences' CRISPR-based engineering biology platform SHERLOCK to design tests to run on Cepheid's GeneXpert systems.

The collaboration will focus on molecular diagnostic tests for infectious diseases and oncology, beginning with a proof-of-concept project focused on the detection of the SARS-CoV-2 virus. Sherlock Biosciences CEO Rahul Dhanda recently told GenomeWeb that the company is working on developing the first CRISPR-based SARS-CoV-2 test and is in talks with a variety of possible partners in the US and China to deploy it at a large scale.

Financial terms of the deal were not disclosed.

"This partnership will allow us to explore utilizing Cepheid's easy-to-use cartridge to further develop targeted molecular tests that better address outbreak scenarios," Cepheid Chief Medical and Technology Officer David Persing said in a statement. "With a global installed base of over 23,000 GeneXpert Systems, this technology could potentially be applied in multiple settings where actionable treatment information is needed quickly."

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.